{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-22-000051","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.207009+00:00","generated_at":"2026-06-24T03:46:08.872069+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Exagen Q2 revenue $9.0M, net loss $13.3M; cuts 2022 guidance to $35-40M","bullets":["AVISE CTD volume hit record 34,919 tests, up 5% YoY and 13% sequentially.","Revenue fell to $9.0M from $12.8M YoY; gross margin dropped to 32.2% from 57.3%.","Net loss widened to $13.3M from $6.4M loss in Q2 2021.","2022 revenue guidance revised to $35-40M, citing Medicare reimbursement uncertainty.","Record 2,273 ordering providers and 797 adopters; ~100M in-network lives under contract."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-22-000051","json":"https://secwatch.observer/filing/0001274737-22-000051.json","markdown":"https://secwatch.observer/filing/0001274737-22-000051.md","text":"https://secwatch.observer/filing/0001274737-22-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473722000051/0001274737-22-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473722000051/exdx-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:46:08.872069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}